Validation of Bulbicam for DR- and AMD-patients

CompletedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

May 1, 2023

Study Completion Date

June 15, 2023

Conditions
Diabetic RetinopathyAge-Related Macular Degeneration
Interventions
DEVICE

BulbiCam

"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."

Trial Locations (1)

0450

Oslo University Hospital, Oslo

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

lead

Meddoc

OTHER

NCT05441072 - Validation of Bulbicam for DR- and AMD-patients | Biotech Hunter | Biotech Hunter